1. Home
  2. COLD vs ACAD Comparison

COLD vs ACAD Comparison

Compare COLD & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Americold Realty Trust Inc.

COLD

Americold Realty Trust Inc.

HOLD

Current Price

$11.25

Market Cap

3.4B

Sector

Real Estate

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.34

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COLD
ACAD
Founded
1903
1993
Country
United States
United States
Employees
12690
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.9B
IPO Year
2009
2000

Fundamental Metrics

Financial Performance
Metric
COLD
ACAD
Price
$11.25
$22.34
Analyst Decision
Buy
Buy
Analyst Count
14
22
Target Price
$15.32
$30.55
AVG Volume (30 Days)
3.9M
1.7M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
8.03%
N/A
EPS Growth
N/A
69.12
EPS
N/A
2.30
Revenue
$2,601,846,000.00
$726,437,000.00
Revenue This Year
N/A
$18.90
Revenue Next Year
$2.86
$11.62
P/E Ratio
N/A
$9.68
Revenue Growth
N/A
40.45
52 Week Low
$10.10
$14.08
52 Week High
$21.27
$28.35

Technical Indicators

Market Signals
Indicator
COLD
ACAD
Relative Strength Index (RSI) 41.73 52.17
Support Level $11.06 $20.35
Resistance Level $11.33 $23.23
Average True Range (ATR) 0.44 0.76
MACD 0.01 0.24
Stochastic Oscillator 38.64 81.50

Price Performance

Historical Comparison
COLD
ACAD

About COLD Americold Realty Trust Inc.

Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 231 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: